GSK Announces Positive Interim Results from Second Head-to-Head Phase III Trial of BCMA ADC Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma

On March 7, GSK (GSK) announced positive interim analysis results from the Phase III head-to-head trial (DREAMM-7), which evaluatedBlenrep(belantamab mafodotin) in combination withPomalidomide+Dexamethasone(PomDex) vs. Standard TreatmentBortezomib+ PomDex for Relapsed or Refractory Multiple Myeloma（R/R MM）The efficacy of second-line and later treatments. In a pre-specified interim analysis, the trial met its primary endpoint of progression-free survival (PFS).

Compared with the standard treatment combination, the Blenrep combination therapy significantly prolonged the time to disease progression or death. A positive overall survival (OS) trend favoring Blenrep combination therapy was also observed at the time of this analysis. The trial will continue follow-up. The safety and tolerability of the Blenrep regimen are generally consistent with the known safety profiles of the individual drugs.

This study is the second head-to-head combination Phase III trial for Blenrep in the second-line and later treatment of MM, following the previous BlenrepThe Phase III DREAMM-7 study for second-line treatment of R/R MM also achieved positive interim results.And with daratumumab (Daratumumab) Combined with BorDex (Bortezomib + Dexamethasone),BlenrepCombined treatment with BorDex can significantly extend the time to disease progression or death for patients.(Recommended reading:BCMA ADC Head-to-Head Daratumumab in Treatment of Multiple Myeloma Successful in Phase III Trial）

Copyright © 2024 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.